London hospital uses new AI tool for cancer detection
Artificial intelligence is helping clinicians enhance the quality of colonoscopies at a London hospital.
The London Clinic has become the UK's first hospital to use GI Genius™, a system that uses AI to detect colorectal polyps. The device acts as a second observer during colonoscopies, helping to assist doctors by identifying lesions and small abnormalities that could be a sign of cancer.
It works by analysing the video stream during the colonoscopy, using advanced AI to highlight the presence of pre-cancerous lesions with a visual marker in real-time. Its creators, medical device company Medtronic, hope it will improve diagnosis and therefore outcomes for patients with colorectal cancer.
Dr Rehan Haidry, Consultant Gastroenterologist at The London Clinic, said: “We are thrilled to introduce the GI Genius™ system at The London Clinic. The system represents an important advancement in technology and is a crucial step in the fight against colorectal cancer, supporting both patients and doctors.
“The technology is incredibly powerful and is proven to be extremely precise in identifying lesions in the colonic mucosa that can be difficult to detect. Some polyps can be very small, and during colonoscopy procedures you are examining the colon, which is five feet long, so it’s vital to be as thorough and diligent as possible.
“Having a second set of eyes that can pick up the smallest change in real-time means we can focus our attention on the right places, which can be life-saving for patients.”
According to the WHO, colorectal cancer is the third most common type worldwide and the second cause of cancer deaths with 862,000 each year. However if detected and treated early it has a high cure rate.
GI Genius™ has been approved for sale in Europe and has started clinical trials for US registration.
NeuTigers: edge AI in healthcare
What is edge AI?
Edge AI is essentially a combination of edge computing and artificial intelligence. Algorithms are processed locally - directly on a mobile device or server - rather than in the cloud. This reduces cost, computing power and energy requirements. There are also claims that edge AI is so fast it is possible to reach near real-time analytics.
Edge AI devices include smart speakers, smart phones, laptops, robots, self-driven cars, drones, and surveillance cameras that use video analytics.
Who is NeuTigers?
NeuTigers is a spin-off company from Princeton University, formed in 2018 to apply edge AI and machine learning to solve challenges in healthcare, energy, productivity, and security.
With offices in Princeton, NJ, the company is based at one of the top AI accelerator programs of FutureLabs in New York, and has also established a subsidiary in Nice, France.
How is NeuTigers applying edge AI to healthcare?
The NeuTigers AI Technology Stack uses deep neural networks that mimic how the human brain perceives and interprets the world. The company has developed the StarDeepTM Smart Health Platform for health monitoring and biomedical imaging, to improve the accuracy and speed of diagnosing diseases.
NeuTigers say the platform has the potential to monitor and screen for thousands of conditions, when used in combination with medical devices and smart sensors already deployed in healthcare settings.
Are there any real world examples?
In January NeuTigers launched CovidDeep, a tool that predicts COVID-19 with more than 90% accuracy, using physiological data from a wristband along with blood pressure and blood oxygen readings. It then analyses the data and gives a prediction within two minutes.
This week NeuTigers announced a new study to detect the early signs of complications with sickle cell anaemia. Conducted at a hospital in Paris, the research will begin by looking at changes to skin response, heart beat, sleep and temperature to predict an acute episode of sickle cell anaemia, and how this impacts on the patients’ disease conditions and quality of life.
The second phase of the project is to expand with prospective studies across different sites in EU, Africa and the US to explore the models' accuracy and clinical effectiveness.
Adel Laoui, CEO and founder of NeuTigers, says: “The best way to deal with a crisis is to avoid it happening in the first place. We are now entering a new era where medical early warning systems have become a reality.
“We are excited at the possibility of deploying a technology that can save lives of patients dealing with sickle cell anaemia. The potential of the StarDeep platform to dramatically improve patient outcomes while slashing some of the highest costs of healthcare makes it one of the most exciting developments in preventative personal medicine.”